Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Yan SB et al. – The proportion of patients with anti–APC antibodies was low and was similar between DAA–treated and placebo–treated patients. No relationship between anti–APC antibody development and adverse reactions was observed. There was no evidence that the anti–APC antibodies detected represented a specific immune response to DAA therapy.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address